Publications by authors named "David Janzen"

Claim this Profile
I
In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment.
Liu Sun, Tim R Eijgenraam, Carl Amilon, David Janzén, Kenny M Hansson

Cardiovasc Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.
Weier Qi, Simina M Boca, Alessandro Boianelli, Monica Fredberg, Sara Lundqvist

J Pharmacol Exp Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration-QTc Modeling Assessment.
Mikael Sunnåker, Christian Källgren, Joanna Parkinson, Corina Dota, Christer Gottfridsson

Pharmacol Res Perspect· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation in pig of an intestinal administration device for oral peptide delivery.
Staffan Berg, Teresia Uggla, Malin Antonsson, Sandro Filipe Nunes, Maria Englund

J Control Release· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of cell-to-cell variation in nuclear transport rates and identification of its sources.
Lucía Durrieu, Alan Bush, Alicia Grande, Rikard Johansson, David Janzén

iScience· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation.
Tim R Eijgenraam, Nienke M Stege, Vivian Oliveira Nunes Teixeira, Remco de Brouwer, Elisabeth M Schouten

Int J Mol Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.
Lars Weidolf, Anders Björkbom, Anders Dahlén, Marie Elebring, Peter Gennemark

Drug Discov Today· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell.
Laurent Knerr, Thazha P Prakash, Richard Lee, William J Drury Iii, Mehran Nikan

J Am Chem Soc· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro and In Vivo Evaluation of 3D Printed Capsules with Pressure Triggered Release Mechanism for Oral Peptide Delivery.
Staffan Berg, Julius Krause, Anders Björkbom, Katrin Walter, Said Harun

J Pharm Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Jesper Sundell, Emile Bienvenu, David Janzén, Sofia Birgersson, Angela Äbelö

Clin Pharmacol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three novel approaches to structural identifiability analysis in mixed-effects models.
David L I Janzén, Mats Jirstrand, Michael J Chappell, Neil D Evans

Comput Methods Programs Biomed· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Luna Prieto Garcia, David Janzén, Kajsa P Kanebratt, Hans Ericsson, Hans Lennernäs

Drug Metab Dispos· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.
Ramon Hendrickx, Eva Lamm Bergström, David L I Janzén, Markus Fridén, Ulf Eriksson

CPT Pharmacometrics Syst Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extending existing structural identifiability analysis methods to mixed-effects models.
David L I Janzén, Mats Jirstrand, Michael J Chappell, Neil D Evans

Math Biosci· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Input Estimation for Extended-Release Formulations Exemplified with Exenatide.
Magnus Trägårdh, Michael J Chappell, Johan E Palm, Neil D Evans, David L I Janzén

Front Bioeng Biotechnol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parameter Identifiability of Fundamental Pharmacodynamic Models.
David L I Janzén, Linnéa Bergenholm, Mats Jirstrand, Joanna Parkinson, James Yates

Front Physiol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it.
Markus Karlsson, David L I Janzén, Lucia Durrieu, Alejandro Colman-Lerner, Maria C Kjellsson

BMC Syst Biol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis